Mismatch repair proteins hMLH1 and hMLH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma

Author(s): Stoehr C, Burger M, Stoehr R, Bertz S, Ruemmele P, et al.


Objectives: We studied the role of minor mismatch repair proteins (MMR) human MutL homologue 1 (hMLH1) and human MutS homologue 2 (hMSH2) in the main subtypes of renal cell carcinoma (RCC). Methods: Expression of MMR proteins hMLH1 and hMSH2 were investigated in 166 RCC tumors, containing the main subtypes by immunohistochemistry. Furthermore, each tumor was screened for microsatellite instability (MSI) using the National Cancer Institute consensus panel for hereditary non-polyposis colon carcinoma as well as for elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) by 10 additional markers. Results: MSI was found only in 2.0% of analyzable cases and EMAST was detected only in 1 patient. hMLH1 and hMSH2 expression was reduced in 83.7 (118/141) and 51.2% (65/127) of cases, respectively, in a subtype-specific manner. None of the clear cell RCC tumors retained a high hMLH1 expression and 92.0% lost hMLH1 completely, while papillary and chromophobe RCC preserved the expression in 25.0 and 33.3% of cases (p < 0.001). Subtype specificity was also present in hMSH2 staining, where chromophobe RCC retained a high expression in 41.7% of cases, while clear cell and papillary tumors did not (29.9 and 23.1%; p = 0.01). Conclusion: MSI and EMAST are rare events in sporadic RCC, whereas diminished MMR protein expression is linked to tumor entity and might contribute to the different biological behavior of the RCC subtypes.

Similar Articles

Survival and prognostic stratification of 670 patients with advanced renal cell carcionma

Author(s): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al.

Nivolumab versus Everolimus in advanced renal-cell carcinoma

Author(s): Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al.

Immunomodulatory activity of Nivolumab in metastatic renal cell carcinoma

Author(s): Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, et al.

DNA mismatch repair genes in renal cell carcinoma

Author(s): Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, et al.

Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors

Author(s): Altavilla G, Fassan M, Busatto G, Orsolan M, Giacomelli L

Mismatch repair gene mutations in renal cell carcinoma

Author(s): Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, et al.

PD-1 blockade in tumors with mismatch-repair deficiency

Author(s): Le D, Uram J, Wang H, Bartlett BR, Kemberling H, et al.

Mismatch repair-deficient cancers are targets for anti-PD-1 therapy

Author(s): Kelderman S, Schumacher TN, Kvistborg P